A comparison of tiotropium 18μg, once daily and ipratropium 40μg, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease

Tuberculosis and Respiratory Diseases

Volumn 58, Issue 5, 2005, Pages 498-506

  Kim, Seung Joon ^a   Kim, Myung Sook ^a   Lee, Sang Haak ^a   Kim, Young Kyoon ^a   Moon, Hwa Sik ^a   Park, Sung Hak ^a,q   Lee, Sang Yeub ^b   In, Kwang Ho ^b   Lee, Chang Youl ^c   Kim, Young Sam ^c   Kim, Hyung Jung ^c   Ahn, Chul Min ^c   Kim, Sung Kyu ^c   Kim, Kyung Rok ^d   Cha, Seung Ick ^d   Jung, Tae Hoon ^d   Kim, Mi Ok ^e   Park, Sung Soo ^e   Choi, Cheon Woong ^f   Yoo, Jee Hong ^f   Kang, Hong Mo ^f   Koh, Won Jung ^g   Ham, Hyoung Suk ^g   Kang, Eun Hae ^g   Kwon, O Jung ^g   Lee, Yang Deok ^h   Lee, Heung Bum ^h   Lee, Yong Chul ^h   Rhee, Yang Keun ^h   Shin, Won Hyuk ⁱ   Kwon, Sung Yeon ⁱ   Kim, Woo Jin ⁱ   Yoo, Chul Gyu ⁱ   Kim, Young Whan ⁱ   Shim, Young Soo ⁱ   Han, Sung Koo ^a   Park, Hye Kyung ⁱ   Kim, Yun Seong ^j   Lee, Min Ki ^j   Park, Soon Kew ^j   Kim, Mi Hye ^k   Lee, Won Yeon ^k   Yong, Suk Joong ^k   Shin, Kye Chul ^k   Choi, Byoung Whui ^l   Oh, Yeon Mok ^m   Lim, Chae Man ^m   Lee, Sang Do ^m   Kim, Woo Sung ^m   Kim, Dong Soon ^m   Jung, Sung Soo ⁿ   Kim, Ju Ock ⁿ   Ko, Young Chun ^o   Kim, Young Chul ^o   Yoo, Nam Soo ^p   more..

^a The Catholic University of Korea   (South Korea)

^b Korea University   (South Korea)

^c Yonsei University   (South Korea)

^d Kyungpook National University   (South Korea)

^e Hanyang University   (South Korea)

^f Kyung Hee University   (South Korea)

^g Sungkyunkwan University   (South Korea)

^h Chonbuk National University   (South Korea)

ⁱ University of Seoul   (South Korea)

^j Pusan National University   (South Korea)

^k Yonsei University Wonju   (South Korea)

^l Chung Ang University   (South Korea)

^m University of Ulsan   (South Korea)

ⁿ Chungnam National University   (South Korea)

^o Chonnam National University   (South Korea)

^p National Medical Center

^q The Catholic University of Korea   (South Korea)

more..

Author keywords

COPD; Efficacy; Ipratropium; Safety; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; IPRATROPIUM BROMIDE; SALBUTAMOL; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BREATHING DISORDER; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 23444452904     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2005.58.5.498     Document Type: Article

References (21)

1. American Thoracic Society Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995;152:S77-S120.
2. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-420.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pultnonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2001.
4. Matera MG, Cazzola M, Vinciguerra A, di Perna F, Calderaro F, Caputi M, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obs-tructive pulmonary disease. Pulm Pharmacol 1995;8: 267-71.
5. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-65.
6. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087-92.
7. LeDoux EJ, Morris JF, Temple WP, Duncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 1989;95:1013-6.
8. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984;311:421-5.
9. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984;129: 856-70.
10. Gross NJ. Ipratropium bromide. N Engl J Med 1988; 319:486-94.
11. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Comelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8: 1506-13.
12. Barnes PJ, Belvisi MG, Mak JC, Haddad EB, O'Connor B. Tiotropium bromide (Ba 679 Br), a novel long-acting muscannic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56:853-9.
13. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.
14. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable COPD. Am J Respir Crit Care Med 2000;161:1136-42.
15. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000;118:1294-302.
16. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-8.
17. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
18. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995;108:1235-9.
19. Giannini D, di Franco A, Bacci E, Dente FL, Bartoli ML, Vagaggini B, et al. Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment. Chest 2001;119:1671-5.
20. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
21. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of COPD. Thorax 2000;55:289-94.